Skip to main content
Top
Published in: Malaria Journal 1/2016

Open Access 01-12-2016 | Commentary

Eliminate now: seven critical actions required to accelerate elimination of Plasmodium falciparum malaria in the Greater Mekong Subregion

Authors: Andrew A. Lover, Roly Gosling, Richard Feachem, Jim Tulloch

Published in: Malaria Journal | Issue 1/2016

Login to get access

Abstract

The emergence in 2009 of Plasmodium falciparum parasites resistant to the primary therapies currently in use (artemisinin-based combination therapy, ACT) in Southeast Asia threatens to set back decades of global progress in malaria control and elimination. Progress to date through multiple sets of initiatives and partners to contain or eliminate these parasites has been hampered due to a wide range of organizational, financial, and health systems-level challenges. In this commentary, a set of seven specific and concrete actions are proposed to directly address these issues and to accelerate P. falciparum elimination within the Greater Mekong Subregion to avert a wider public health crisis. These actions are specifically needed to elevate the situation and response mechanisms to those of a true emergency; to address systems-level challenges with personnel limitations and stock-outs of key commodities; and to restructure the response mechanisms to be well-aligned with the required outcomes. Consideration of these issues is especially pressing with planning meetings for renewal of the Regional Artemisinin-resistance Initiative (RAI) framework slated for late 2016 and into 2017, but these suggestions are also relevant for malaria programmes globally.
Literature
3.
go back to reference Miotto O, Almagro-Garcia J, Manske M, MacInnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013;45:648–55.CrossRefPubMed Miotto O, Almagro-Garcia J, Manske M, MacInnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013;45:648–55.CrossRefPubMed
4.
go back to reference Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–21.CrossRefPubMedPubMedCentral Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–21.CrossRefPubMedPubMedCentral
5.
go back to reference Djimde AA, Makanga M, Kuhen K, Hamed K. The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine. Expert Rev Anti Infect Ther. 2015;13:1031–45.CrossRefPubMed Djimde AA, Makanga M, Kuhen K, Hamed K. The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine. Expert Rev Anti Infect Ther. 2015;13:1031–45.CrossRefPubMed
6.
go back to reference Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–26.CrossRefPubMedPubMedCentral Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–26.CrossRefPubMedPubMedCentral
7.
go back to reference Gueye CS, Newby G, Hwang J, Phillips AA, Whittaker M, MacArthur JR, et al. The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J. 2014;13:286.CrossRef Gueye CS, Newby G, Hwang J, Phillips AA, Whittaker M, MacArthur JR, et al. The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J. 2014;13:286.CrossRef
10.
go back to reference Heymann DL, Hodgson A, Freedman DO, Staples JE, Althabe F, Baruah K, et al. Zika virus and microcephaly: why is this situation a PHEIC? Lancet. 2016;387:719–21.CrossRefPubMed Heymann DL, Hodgson A, Freedman DO, Staples JE, Althabe F, Baruah K, et al. Zika virus and microcephaly: why is this situation a PHEIC? Lancet. 2016;387:719–21.CrossRefPubMed
11.
go back to reference MalariaGEN Plasmodium falciparum community project. Genomic epidemiology of artemisinin resistant malaria. eLife. 2016; 5:e08714. MalariaGEN Plasmodium falciparum community project. Genomic epidemiology of artemisinin resistant malaria. eLife. 2016; 5:e08714.
12.
go back to reference Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12–7.PubMed Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12–7.PubMed
13.
go back to reference Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15:10.CrossRefPubMedPubMedCentral Slater HC, Griffin JT, Ghani AC, Okell LC. Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malar J. 2016;15:10.CrossRefPubMedPubMedCentral
14.
go back to reference Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci. 2004;359:1091–105.CrossRefPubMedPubMedCentral Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci. 2004;359:1091–105.CrossRefPubMedPubMedCentral
15.
go back to reference Foster SO, Ward NA, Joarder AK, Arnt N, Tarantola D, Rahman M, et al. Smallpox surveillance in Bangladesh: development of surveillance containment strategy. Int J Epidemiol. 1980;9:329–34.CrossRefPubMed Foster SO, Ward NA, Joarder AK, Arnt N, Tarantola D, Rahman M, et al. Smallpox surveillance in Bangladesh: development of surveillance containment strategy. Int J Epidemiol. 1980;9:329–34.CrossRefPubMed
17.
go back to reference Pampana E. A textbook of malaria eradication. 2nd ed. London: Oxford University Press; 1969. Pampana E. A textbook of malaria eradication. 2nd ed. London: Oxford University Press; 1969.
19.
go back to reference Canavati SE, Lawpoolsri S, Quintero CE, Nguon C, Ly P, Pukrittayakamee S, et al. Village malaria worker performance key to the elimination of artemisinin-resistant malaria: a Western Cambodia health system assessment. Malar J. 2016;15:282.CrossRefPubMedPubMedCentral Canavati SE, Lawpoolsri S, Quintero CE, Nguon C, Ly P, Pukrittayakamee S, et al. Village malaria worker performance key to the elimination of artemisinin-resistant malaria: a Western Cambodia health system assessment. Malar J. 2016;15:282.CrossRefPubMedPubMedCentral
20.
21.
22.
go back to reference Cox J, Sovannaroth S, Dy Soley L, Ngor P, Mellor S, Roca-Feltrer A. Novel approaches to risk stratification to support malaria elimination: an example from Cambodia. Malar J. 2014;13:371.CrossRefPubMedPubMedCentral Cox J, Sovannaroth S, Dy Soley L, Ngor P, Mellor S, Roca-Feltrer A. Novel approaches to risk stratification to support malaria elimination: an example from Cambodia. Malar J. 2014;13:371.CrossRefPubMedPubMedCentral
23.
go back to reference Kok MC, Dieleman M, Taegtmeyer M, Broerse JE, Kane SS, Ormel H, et al. Which intervention design factors influence performance of community health workers in low- and middle-income countries? A systematic review. Health Policy Plan. 2015;30:1207–27.CrossRefPubMed Kok MC, Dieleman M, Taegtmeyer M, Broerse JE, Kane SS, Ormel H, et al. Which intervention design factors influence performance of community health workers in low- and middle-income countries? A systematic review. Health Policy Plan. 2015;30:1207–27.CrossRefPubMed
24.
go back to reference Melgaard B, Creese A, Aylward B, Olive JM, Maher C, Okwo-Bele JM, et al. Disease eradication and health systems development. Bull World Health Organ. 1998;76:26–31.PubMedPubMedCentral Melgaard B, Creese A, Aylward B, Olive JM, Maher C, Okwo-Bele JM, et al. Disease eradication and health systems development. Bull World Health Organ. 1998;76:26–31.PubMedPubMedCentral
25.
go back to reference Eichler R, Levine R. Performance incentives for global health: potential and pitfalls. 1st ed. Washington, DC: Center for Global Development Books; 2009. Eichler R, Levine R. Performance incentives for global health: potential and pitfalls. 1st ed. Washington, DC: Center for Global Development Books; 2009.
26.
go back to reference Gosling J, Case P, Tulloch J, Chandramohan D, Wegbreit J, Newby G, et al. Effective program management: a cornerstone of malaria elimination. Am J Trop Med Hyg. 2015;93:135–8.CrossRefPubMedPubMedCentral Gosling J, Case P, Tulloch J, Chandramohan D, Wegbreit J, Newby G, et al. Effective program management: a cornerstone of malaria elimination. Am J Trop Med Hyg. 2015;93:135–8.CrossRefPubMedPubMedCentral
27.
go back to reference Garcia R, Hewitt S, Tulloch J. Report of the independent review of the Global Fund Regional Artemisinin-resistance Initiative (RAI). Geneva: The Global Fund; 2015. Garcia R, Hewitt S, Tulloch J. Report of the independent review of the Global Fund Regional Artemisinin-resistance Initiative (RAI). Geneva: The Global Fund; 2015.
28.
go back to reference Greenough P. Intimidation, coercion and resistance in the final stages of the South Asian Smallpox Eradication Campaign, 1973–1975. Soc Sci Med. 1995;41:633–45.CrossRefPubMed Greenough P. Intimidation, coercion and resistance in the final stages of the South Asian Smallpox Eradication Campaign, 1973–1975. Soc Sci Med. 1995;41:633–45.CrossRefPubMed
29.
30.
go back to reference Gladwell M. Fred Soper and the global malaria eradication programme. J Public Health Policy. 2002;23:479–97.CrossRefPubMed Gladwell M. Fred Soper and the global malaria eradication programme. J Public Health Policy. 2002;23:479–97.CrossRefPubMed
32.
go back to reference Bruce-Chwatt LJ. Essential malariology. 2nd ed. New York: Wiley; 1985. Bruce-Chwatt LJ. Essential malariology. 2nd ed. New York: Wiley; 1985.
33.
go back to reference Zhao J, Lama M, Sarkar S, Atun R. Indicators measuring the performance of malaria programs supported by the global fund in Asia, progress and the way forward. PLoS ONE. 2011;6:e28932.CrossRefPubMedPubMedCentral Zhao J, Lama M, Sarkar S, Atun R. Indicators measuring the performance of malaria programs supported by the global fund in Asia, progress and the way forward. PLoS ONE. 2011;6:e28932.CrossRefPubMedPubMedCentral
34.
go back to reference Soper FL, Wilson DB. Anopheles gambiae in Brazil 1930 to 1940. 1st ed. New York: The Rockefeller Foundation; 1943. Soper FL, Wilson DB. Anopheles gambiae in Brazil 1930 to 1940. 1st ed. New York: The Rockefeller Foundation; 1943.
Metadata
Title
Eliminate now: seven critical actions required to accelerate elimination of Plasmodium falciparum malaria in the Greater Mekong Subregion
Authors
Andrew A. Lover
Roly Gosling
Richard Feachem
Jim Tulloch
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2016
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-016-1564-3

Other articles of this Issue 1/2016

Malaria Journal 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.